Hemodynamics, fluids & transfusion
Argipressin for prevention of blood loss in hepatic resection: a randomised, placebo-controlled, double-blind trial
Primary result · Blood loss during surgeryResult — go to the resultAdjusted relative risk 0.90 95% CI 0.70–1.17Authors' conclusion
Perioperative treatment with argipressin did not reduce blood loss or transfusion requirements in hepatic resection.
Study context
- Population
- Adults undergoing hepatic resection, Sahlgrenska University Hospital, Swedenprimary analysis
- Participants
- 245 adults
- Comparison
- Argipressin infusion vs placebo during surgery
- Argipressinn = 119
- Placebon = 126reference
- Primary endpoint
- Blood loss (ml) during surgery
Methodological detailssingle-centre, placebo-controlled, double-blind
- Single-centre
- Placebo-controlled
- Double-blind
Primary result
Blood loss during surgery
Adjusted relative risk
0.90
95% CI 0.70–1.17
P = 0.44
By group
Argipressin vs Placebo
adjusted RR 0.90 (95% CI 0.70–1.17); P = 0.44
As reported in the abstract
Secondary outcomes
| Outcome | Argipressin | Placebo | aOR (95% CI) | P value | |
|---|---|---|---|---|---|
| RBC transfusion | 36.8% | 41.3% | 0.84 (0.48–1.49) | P = 0.56 | |
| 0.512Adjusted odds ratio (log scale) |
Safety
| Outcome | Argipressin | Placebo | aOR (95% CI) | P value | |
|---|---|---|---|---|---|
| Postoperative complications · POD 30 | 38.8% | 58.1% | 0.43 (0.25–0.74) | P = 0.0025 | |
| 0.20.5125Adjusted odds ratio (log scale) |
Original publication
Argipressin for prevention of blood loss in hepatic resection: a randomised, placebo-controlled, double-blind trial. Br J Anaesth. Published 30 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →